vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
13.48
-0.48 (-3.44%)
Jan 22, 2025, 4:00 PM EST - Market closed
vTv Therapeutics Revenue
vTv Therapeutics had revenue of $1.00M in the twelve months ending September 30, 2024, up 11,011.11% year-over-year.
Revenue (ttm)
$1.00M
Revenue Growth
+11,011.11%
P/S Ratio
35.21
Revenue / Employee
$62,500
Employees
16
Market Cap
43.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.02M | -1.99M | -49.61% |
| Dec 31, 2021 | 4.01M | -2.41M | -37.56% |
| Dec 31, 2020 | 6.41M | 3.65M | 132.05% |
| Dec 31, 2019 | 2.76M | -9.67M | -77.77% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.95B |
VTVT News
- 6 weeks ago - CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER - PRNewsWire
- 7 weeks ago - vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference - GlobeNewsWire
- 5 months ago - vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold - GlobeNewsWire
- 7 months ago - vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes - GlobeNewsWire
- 8 months ago - CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING - PRNewsWire
- 9 months ago - vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 11 months ago - CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT - PRNewsWire